Annual accounts receivable:
$11.46B-$103.00M(-0.89%)Summary
- As of today (June 22, 2025), PFE annual accounts receivable is $11.46 billion, with the most recent change of -$103.00 million (-0.89%) on December 31, 2024.
- During the last 3 years, PFE annual accounts receivable has fallen by -$16.00 million (-0.14%).
- PFE annual accounts receivable is now -21.73% below its all-time high of $14.64 billion, reached on December 31, 2009.
Performance
PFE Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$11.85B+$382.00M(+3.33%)Summary
- As of today (June 22, 2025), PFE quarterly accounts receivable is $11.85 billion, with the most recent change of +$382.00 million (+3.33%) on March 29, 2025.
- Over the past year, PFE quarterly accounts receivable has increased by +$856.00 million (+7.79%).
- PFE quarterly accounts receivable is now -26.32% below its all-time high of $16.08 billion, reached on September 1, 2022.
Performance
PFE Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
PFE Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -0.9% | +7.8% |
| 3 y3 years | -0.1% | -10.4% |
| 5 y5 years | +69.3% | +19.9% |
PFE Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -0.9% | +4.7% | -26.3% | +15.8% |
| 5 y | 5-year | -0.9% | +69.3% | -26.3% | +49.7% |
| alltime | all time | -21.7% | +138.9% | -26.3% | +146.9% |
PFE Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $11.85B(+3.3%) |
| Dec 2024 | $11.46B(-0.9%) | $11.46B(-20.7%) |
| Sep 2024 | - | $14.45B(+26.8%) |
| Jun 2024 | - | $11.39B(+3.7%) |
| Mar 2024 | - | $10.99B(-5.0%) |
| Dec 2023 | $11.57B(+5.6%) | $11.57B(+4.3%) |
| Sep 2023 | - | $11.09B(+8.4%) |
| Jun 2023 | - | $10.23B(-16.9%) |
| Mar 2023 | - | $12.30B(+12.4%) |
| Dec 2022 | $10.95B(-4.6%) | $10.95B(-31.9%) |
| Sep 2022 | - | $16.08B(+6.1%) |
| Jun 2022 | - | $15.15B(+14.6%) |
| Mar 2022 | - | $13.22B(+15.2%) |
| Dec 2021 | $11.48B(+45.1%) | $11.48B(-3.5%) |
| Sep 2021 | - | $11.90B(+12.4%) |
| Jun 2021 | - | $10.59B(+7.3%) |
| Mar 2021 | - | $9.86B(+24.7%) |
| Dec 2020 | $7.91B(+16.8%) | $7.91B(-21.0%) |
| Sep 2020 | - | $10.01B(+9.7%) |
| Jun 2020 | - | $9.13B(-7.6%) |
| Mar 2020 | - | $9.88B(+45.9%) |
| Dec 2019 | $6.77B(-15.6%) | $6.77B(-28.3%) |
| Sep 2019 | - | $9.44B(-3.6%) |
| Jun 2019 | - | $9.79B(+2.0%) |
| Mar 2019 | - | $9.60B(+19.6%) |
| Dec 2018 | $8.03B(-2.4%) | $8.03B(-19.9%) |
| Sep 2018 | - | $10.02B(+1.5%) |
| Jun 2018 | - | $9.87B(+4.5%) |
| Mar 2018 | - | $9.45B(+15.0%) |
| Dec 2017 | $8.22B(-0.0%) | $8.22B(-17.8%) |
| Sep 2017 | - | $10.00B(+5.6%) |
| Jun 2017 | - | $9.48B(+6.6%) |
| Mar 2017 | - | $8.89B(+8.1%) |
| Dec 2016 | $8.22B(+0.6%) | $8.22B(-16.4%) |
| Sep 2016 | - | $9.84B(+7.6%) |
| Jun 2016 | - | $9.14B(+1.2%) |
| Mar 2016 | - | $9.03B(+10.5%) |
| Dec 2015 | $8.18B(-2.7%) | $8.18B(-14.3%) |
| Sep 2015 | - | $9.54B(+6.5%) |
| Jun 2015 | - | $8.95B(+0.3%) |
| Mar 2015 | - | $8.92B(+6.2%) |
| Dec 2014 | $8.40B(-10.2%) | $8.40B(-15.6%) |
| Sep 2014 | - | $9.96B(-4.2%) |
| Jun 2014 | - | $10.39B(+10.5%) |
| Mar 2014 | - | $9.40B(+0.4%) |
| Dec 2013 | $9.36B(-12.3%) | $9.36B(-17.7%) |
| Sep 2013 | - | $11.37B(-1.3%) |
| Jun 2013 | - | $11.52B(-9.5%) |
| Mar 2013 | - | $12.73B(+19.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $10.68B(-18.2%) | $10.68B(-14.8%) |
| Sep 2012 | - | $12.52B(-2.8%) |
| Jun 2012 | - | $12.88B(-9.2%) |
| Mar 2012 | - | $14.18B(+8.6%) |
| Dec 2011 | $13.06B(-10.6%) | $13.06B(-17.1%) |
| Sep 2011 | - | $15.75B(+3.7%) |
| Jun 2011 | - | $15.19B(+0.1%) |
| Mar 2011 | - | $15.18B(+3.9%) |
| Dec 2010 | $14.61B(-0.2%) | $14.61B(+2.2%) |
| Sep 2010 | - | $14.30B(+2.1%) |
| Jun 2010 | - | $14.01B(+2.9%) |
| Mar 2010 | - | $13.61B(-7.1%) |
| Dec 2009 | $14.64B(+63.5%) | $14.64B(+38.8%) |
| Sep 2009 | - | $10.55B(+1.0%) |
| Jun 2009 | - | $10.45B(+8.9%) |
| Mar 2009 | - | $9.60B(+7.1%) |
| Dec 2008 | $8.96B(-9.0%) | $8.96B(-9.5%) |
| Sep 2008 | - | $9.90B(-3.4%) |
| Jun 2008 | - | $10.24B(-1.8%) |
| Mar 2008 | - | $10.43B(+6.0%) |
| Dec 2007 | $9.84B(+4.8%) | $9.84B(-1.0%) |
| Sep 2007 | - | $9.94B(+4.7%) |
| Jun 2007 | - | $9.50B(-9.2%) |
| Mar 2007 | - | $10.46B(+11.3%) |
| Dec 2006 | $9.39B(+3.2%) | $9.39B(+2.3%) |
| Sep 2006 | - | $9.18B(-1.1%) |
| Jun 2006 | - | $9.28B(-10.4%) |
| Mar 2006 | - | $10.35B(+13.7%) |
| Dec 2005 | $9.10B(-2.8%) | $9.10B(-2.6%) |
| Sep 2005 | - | $9.35B(+0.3%) |
| Jun 2005 | - | $9.32B(-7.5%) |
| Mar 2005 | - | $10.07B(+7.5%) |
| Dec 2004 | $9.37B(+8.5%) | $9.37B(+1.6%) |
| Sep 2004 | - | $9.22B(-1.3%) |
| Jun 2004 | - | $9.34B(-10.3%) |
| Mar 2004 | - | $10.41B(+20.6%) |
| Dec 2003 | $8.64B(+49.3%) | $8.64B(+0.1%) |
| Sep 2003 | - | $8.63B(-2.1%) |
| Jun 2003 | - | $8.81B(+30.3%) |
| Mar 2003 | - | $6.76B(+16.8%) |
| Dec 2002 | $5.79B(+20.6%) | $5.79B(-5.1%) |
| Sep 2002 | - | $6.10B(-2.8%) |
| Jun 2002 | - | $6.27B(-2.8%) |
| Mar 2002 | - | $6.45B(+34.5%) |
| Dec 2001 | $4.80B(-12.6%) | $4.80B(-15.5%) |
| Sep 2001 | - | $5.68B(+4.5%) |
| Jun 2001 | - | $5.43B(-5.9%) |
| Mar 2001 | - | $5.77B(+5.2%) |
| Dec 2000 | $5.49B(+2.3%) | $5.49B(+2.3%) |
| Dec 1999 | $5.37B | $5.37B |
FAQ
- What is Pfizer annual accounts receivable?
- What is the all time high annual accounts receivable for Pfizer?
- What is Pfizer annual accounts receivable year-on-year change?
- What is Pfizer quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Pfizer?
- What is Pfizer quarterly accounts receivable year-on-year change?
What is Pfizer annual accounts receivable?
The current annual accounts receivable of PFE is $11.46B
What is the all time high annual accounts receivable for Pfizer?
Pfizer all-time high annual accounts receivable is $14.64B
What is Pfizer annual accounts receivable year-on-year change?
Over the past year, PFE annual accounts receivable has changed by -$103.00M (-0.89%)
What is Pfizer quarterly accounts receivable?
The current quarterly accounts receivable of PFE is $11.85B
What is the all time high quarterly accounts receivable for Pfizer?
Pfizer all-time high quarterly accounts receivable is $16.08B
What is Pfizer quarterly accounts receivable year-on-year change?
Over the past year, PFE quarterly accounts receivable has changed by +$856.00M (+7.79%)